Asset Details
Do you wish to reserve the book?
PRDM6 promotes medulloblastoma by repressing chromatin accessibility and altering gene expression
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
PRDM6 promotes medulloblastoma by repressing chromatin accessibility and altering gene expression
Do you wish to request the book?
PRDM6 promotes medulloblastoma by repressing chromatin accessibility and altering gene expression
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
PRDM6 promotes medulloblastoma by repressing chromatin accessibility and altering gene expression
2024
Overview
SNCAIP
duplication may promote Group 4 medulloblastoma via induction of PRDM6, a poorly characterized member of the
PRDF1 and RIZ1 homology domain-containing
(PRDM) family of transcription factors. Here, we investigated the function of PRDM6 in human hindbrain neuroepithelial stem cells and tested PRDM6 as a driver of Group 4 medulloblastoma. We report that human PRDM6 localizes predominantly to the nucleus, where it causes widespread repression of chromatin accessibility and complex alterations of gene expression patterns. Genome-wide mapping of PRDM6 binding reveals that PRDM6 binds to chromatin regions marked by histone H3 lysine 27 trimethylation that are located within, or proximal to, genes. Moreover, we show that PRDM6 expression in neuroepithelial stem cells promotes medulloblastoma. Surprisingly, medulloblastomas derived from PRDM6-expressing neuroepithelial stem cells match human Group 3, but not Group 4, medulloblastoma. We conclude that PRDM6 expression has oncogenic potential but is insufficient to drive Group 4 medulloblastoma from neuroepithelial stem cells. We propose that both PRDM6 and additional factors, such as specific cell-of-origin features, are required for Group 4 medulloblastoma. Given the lack of PRDM6 expression in normal tissues and its oncogenic potential shown here, we suggest that PRDM6 inhibition may have therapeutic value in PRDM6-expressing medulloblastomas.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 631/67
/ Animals
/ Cerebellar Neoplasms - genetics
/ Cerebellar Neoplasms - metabolism
/ Cerebellar Neoplasms - pathology
/ Gene Expression Regulation, Neoplastic
/ Histone-Lysine N-Methyltransferase - genetics
/ Histone-Lysine N-Methyltransferase - metabolism
/ Histones
/ Homology
/ Humanities and Social Sciences
/ Humans
/ Medulloblastoma - metabolism
/ Neuroepithelial Cells - metabolism
/ Science
